Retin-A Shortage: What Providers and Prescribers Need to Know in 2026

Topical tretinoin remains one of the most prescribed dermatological medications in the United States, with demand continuing to grow driven by telehealth expansion and patient interest in evidence-based skincare. While the FDA has not declared a formal shortage of topical tretinoin in 2026, pharmacists and patients report inconsistent availability that is affecting prescription fill rates. This guide is designed to help prescribers proactively manage patient access.

Current Availability Landscape

The FDA Drug Shortage Database does not list topical tretinoin (cream, gel, or lotion) as being in shortage as of 2026. The existing FDA shortage listing is for oral tretinoin capsules used in APL treatment — a completely separate product.

However, a number of structural factors are creating real pharmacy-level availability gaps:

• Demand surge: Telehealth platforms have dramatically increased tretinoin prescription volume. The global tretinoin market was valued at $1.8 billion in 2025, projected to reach $3.2 billion by 2034 at a CAGR of 6.6%.
• Supply fragmentation: Retin-A is available in cream, gel, and microsphere gel formulations across concentrations of 0.01% to 0.1%. Stocking gaps often affect specific strengths or formulations rather than the drug class broadly.
• Generic market expansion: New generic manufacturers are entering the market. Alembic launched a generic tretinoin 0.1% cream in June 2024, increasing supply diversity. However, individual manufacturers' production schedules can still create localized gaps.

Prescribing Strategies to Improve Patient Fill Rates

The following strategies can significantly reduce the likelihood of a failed fill:

1. Write for generic tretinoin rather than brand-name Retin-A. Multiple manufacturers produce generic tretinoin, giving the pharmacist flexibility to dispense whichever formulation is in stock. Unless there's a clinical reason to specify the brand (e.g., a patient who needs Retin-A Micro for its microsponge delivery), generic prescriptions are more likely to be filled without delay.
2. Prescribe with therapeutic substitution allowance. Note on the prescription that the pharmacist may dispense a comparable concentration (e.g., 0.025% or 0.05% if 0.1% is unavailable) with prescriber approval. Establishing this flexibility upfront can prevent callbacks and delays.
3. Counsel patients to check stock before transferring the prescription. Advise patients to confirm availability before you send the prescription electronically. Tools like medfinder can check multiple pharmacies at once.
4. Consider 90-day supplies. For established patients on maintenance therapy, 90-day fills reduce the frequency of refill-related gaps.
5. Establish a compounding pharmacy relationship. A reliable compounding pharmacy can fill custom tretinoin concentrations when commercial products are unavailable. This is particularly useful for patients who need concentrations outside the standard commercial range.

Bridge Therapies When Tretinoin Is Unavailable

For patients who cannot fill their tretinoin prescription and need an interim therapeutic option:

• Adapalene 0.1% (Differin) OTC: Available without a prescription. Roughly equivalent to tretinoin 0.025% gel for acne. Lower irritation profile, good tolerability. A reasonable bridge for most acne patients.
• Adapalene 0.3% (Rx): Prescription strength with stronger efficacy data, particularly for inflammatory lesions. Better tolerated than tretinoin in head-to-head trials.
• Tazarotene 0.045% foam (Arazlo) or 0.1% gel (Tazorac): Clinically superior to tretinoin 0.025% for some measures but with higher irritation risk. Consider for patients with moderate-to-severe acne who have demonstrated retinoid tolerance.
• Azelaic acid (15% gel or 20% cream): Anti-inflammatory, antibacterial, and mild keratolytic. A good alternative for patients with sensitive skin, rosacea, or post-inflammatory hyperpigmentation.

Cost and Access Considerations for Patients

When counseling patients about tretinoin costs in 2026:

• Generic tretinoin 0.025% cream: $28–$47 with GoodRx at major retailers (Walmart, Kroger, CVS). Retail cash price can be $70–$95 without a coupon.
• Insurance: Most plans cover generic tretinoin (Tier 1-2) for acne indications with a $0–$30 copay. Coverage for photoaging or cosmetic use is typically denied.
• Brand Retin-A and Retin-A Micro: $200–$400+ without insurance. Manufacturer savings cards from Ortho Dermatologics (Bausch Health) may reduce out-of-pocket cost substantially for commercially insured patients.

How medfinder Supports Prescribers

medfinder's provider platform allows practices to check pharmacy stock for tretinoin and other medications. By directing patients to specific pharmacies known to carry their prescription, practices can reduce failed fill attempts, patient callbacks, and prescriber workload. Learn more at medfinder for providers.

Key Takeaways for Providers

• No FDA shortage of topical tretinoin exists in 2026 — pharmacy-level gaps are due to demand and stocking practices
• Prescribing generic and allowing therapeutic substitution significantly improves fill rates
• Adapalene 0.1% OTC and tazarotene are the most clinically appropriate bridge therapies
• Compounding pharmacies can fill custom strengths when commercial supply is inadequate
• medfinder can help direct patients to pharmacies with confirmed stock, reducing failed fill attempts